Insider Selling: Arcus Biosciences (NYSE:RCUS) CEO Sells 25,744 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CEO Terry Rosen sold 25,744 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total transaction of $570,487.04. Following the completion of the sale, the chief executive officer owned 2,194,809 shares of the company’s stock, valued at approximately $48,636,967.44. The trade was a 1.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Arcus Biosciences Stock Performance

NYSE RCUS traded down $0.26 on Thursday, hitting $22.02. 1,175,874 shares of the company’s stock were exchanged, compared to its average volume of 1,200,446. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of -6.40 and a beta of 0.75. The firm’s 50-day moving average price is $20.82 and its two-hundred day moving average price is $13.98. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $26.40. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The firm had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.Arcus Biosciences’s quarterly revenue was down 45.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.00) earnings per share. On average, research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank grew its stake in Arcus Biosciences by 3.9% in the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock worth $266,000 after acquiring an additional 736 shares during the period. Creative Planning grew its position in shares of Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after purchasing an additional 771 shares during the period. GAMMA Investing LLC lifted its position in Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after buying an additional 1,021 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Arcus Biosciences by 8.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock worth $142,000 after buying an additional 1,294 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in Arcus Biosciences by 1.6% in the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock valued at $716,000 after buying an additional 1,422 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

RCUS has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. HC Wainwright increased their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Friday, December 12th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a report on Monday. Finally, Bank of America lifted their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.89.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.